ACADIA Pharmaceuticals Inc. news

   Watch this stock
Showing stories 1 - 10 of about 80   

Articles published

ACAD 32.59 -0.76 (-2.28%)
price chart
Palo Alto Networks Inc, ACADIA Pharmaceuticals Inc., Shake Shack Inc: Stocks ...
You would have been hard-pressed to find many analysts la-belling Tesla Motors Inc. (Nasdaq: TSLA) a �Sell� last September.
Stocks Investor's Alert: ACADIA Pharmaceuticals (NASDAQ:ACAD), Norwegian ...
On Friday, Following Stocks were among the �Top 100 Gainers� of U.S. Stock Market: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), Norwegian Cruise Line Holdings Ltd.
Company Update (NASDAQ:ACAD): ACADIA Pharmaceuticals Inc. Appoints ...
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, ...
ACADIA Pharmaceuticals At $30: The Upside Doesn't Justify The Risk  Seeking Alpha (registration)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Acadia ...  CNNMoney
Deadline in Lawsuit for Investors in ACADIA Pharmaceuticals Inc. (NASDAQ ...
SAN DIEGO, March 18, 2015 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit was filed on behalf of certain purchasers of shares of ACADIA Pharmaceuticals Inc. (ACAD) over alleged Federal Securities Laws Violations by ...
Deadline in Lawsuit for Investors in ACADIA Pharmaceuticals Inc. ACAD Shares ...  MarketWatch
Trader's Recap on Positive Approaches: ACADIA Pharmaceuticals (ACAD ...
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders.
Recent Analysts' Ratings Changes for ACADIA Pharmaceuticals (ACAD)  WKRB News
Calls Hot as ACADIA Pharmaceuticals Inc. (ACAD) Explores New Territory
Despite a broad-market bloodbath, ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is continuing its hunt for higher highs today. The stock topped out at a record peak of $44.55 earlier, and was last seen up 13.8% at $44.29.
Acadia Pharmaceuticals Buyout Will Happen, Just Not Yet (ACAD)  Seeking Alpha (registration)
Acadia Surges as Canceled Events Lead to Deal Speculation  Bloomberg
Acadia Pharmaceuticals Inc. Investors Encouraged to Contact Securities Law ...
NEW YORK, March 16, 2015 /PRNewswire/ -- Securities lawyers at Dunnam & Dunnam are investigating allegations for Acadia Pharmaceuticals Inc. shareholders (NASDAQ: ACAD). Concerned ACAD investors who purchased between January 13, 2015 and ...
Hagens Berman Alerts ACADIA Pharmaceuticals, Inc. ACAD Investors With Over ...
Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, advises investors with losses exceeding $100,000 of the May 12, 2015 lead plaintiff deadline in a class action lawsuit filed against ACADIA Pharmaceuticals, Inc. ACAD, -1.34 ...
Hagens Berman Alerts ACADIA Pharmaceuticals, Inc. (NASDAQ:ACAD ...  GlobeNewswire (press release)
Superconductor Technologies, Inc. (SCON), Pfizer Inc. (PFE), ACADIA ...
The most notable of these long positions are represented by Pfizer Inc. (NYSE:PFE), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), and Merck & Co.
Harwood Feffer LLP Announces Investigation of Acadia Pharmaceuticals Inc.
NEW YORK, March 12, 2015 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Acadia Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD), concerning whether the board ...